Affordable therapeutics for life-threatening diseases
Cell-Easy is a stem cell Contract Development and Manufacturing Organization (CDMO) that provides quick and easy access to ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development projects. Our production process has been optimized under cGMP conditions, in order to be scalable and guarantee optimal product safety, quality and efficacy for your patients.
One single donor to help thousands of patients
We produce custom-developed cryopreserved adipose-derived stem cells in vials and deliver them to your doorstep.
Our unique, allogeneic and scalable production process allows us to use the biological material of one single healthy volunteering donor to help thousands of patients. Our stem cell products can be used in regenerative medicine but also in a wider range of human health projects.
The vials are ready-to-inject to avoid unnecessary manipulations in order to help your Investigational Medicinal Product (IMP) on the road to success without compromising on quality.
Custom therapeutics from adipose-derived stromal stem cells
Our cGMP platform holds 330m2 class B cleanrooms and provides ample production capacity to set up trials for over 10,000 patients per year.
To help you on your way to perform quick and easy clinical trials, with high-quality products that also allow you to cut down on costs, Cell-Easy is also able to carry out:
Clear answers and timelines to fit your requirements
We respect your clinical trial requirements and product expectations in terms of dosage and formulation to develop a custom, high-quality product for your clinical trial. Our expert team evaluates all your requirements and gives you clear answers and timelines.
We help you on your way to affordable cell therapy for life-threatening diseases:
Guillaume Costecalde, Msc, MBA
Over 20 years of experience in biotech entrepreneurship. He started his entrepreneurial career at the Genopole Evry, France’s leading biotech cluster. Founder of Physiogenex and Univercell-Biosolutions (now Human cell design) start-up companies focused on translational medicine and stem cells.
Pierre Monsan, PhD
Chief Executive Officer / Chief Scientific Officer
He has an outstanding track record of achievements both in the Academic field (250 articles and 65 patents, Biocat Award 2012, Enzyme Engineering Award 2017) and entrepreneurship (co-founder of BioEurope 1984, Biotrade 1996, Genibio 1998, founder of Toulouse White Biotechnology – TWB – 2012). He is an expert in Bioproduction.
Hélène Brochot-Dechet, PharmD
Qualified Person & Head of Quality
Hélène started her career as a development project manager for Pierre Fabre Dermo-Cosmétique and has also worked as Head of quality control for Advanced Therapy Medicinal Products (ATMPs) for the Etablissement Français du Sang Occitanie. She has over 18 years of experience in project development, GMP-grade production, quality control, quality assurance and regulatory matters.
Philippe Bourin, MD, PhD
Senior Expert Mesenchymal Stem Cell biology, production & therapy
Thanks to his ground-breaking work on early protocols for adipose stromal cells clinical production, Philippe is a well-known figure in the field of stem cells. Earlier in his career, he worked as the Production Director for the Etablissement Français du Sang Occitanie. Philippe has over 30 years of experience and know-how in human cell biology and culture.
Head of Bioprocess Development and Manufacturing
Laura brings 10 years of experience in bioprocess development and manufacturing. Graduated in Biotech Engineering, she previously worked for UCB Pharma, first as an Upstream Process Development Scientist, and then as an External Manufacturing Lead. She has experience with early and late stage CMC development of biological products, process tech transfer and validation, and international project management.
Business Development Manager
Engineer in Biochemistry from INSA (Lyon-France), Michel Manach has worked internationally in leader companies developing tools for the Biotechnologies, mainly for the bioprocessing. He managed French companies and developed key accounts worldwide. Recently, he successfully developed the business of TWB, a structure at the interface between industries and academic research in the field of industrial Biotechnology.